Page 72 - Škrgat, Sabina, ed. 2023. Severe Asthma Forum - Monitoring and Treatable Traits in Severe Asthma. Koper: University of Primorska Press. Severe Asthma Forum, 2
P. 72
cessfully51. Previous reports on therapeutic re- 5. Albendiz VJ, de Castro FJ, Gutierrez IG
sponses have not provided accurate answers et al. Characteristics of patients with se-
severe asthma forum 2: severe asthma - monitoring and treatable traits in severe asthma to a number of questions about long-term bi- vere asthma in our population. J Aller-
ological treatment in daily clinical practice. gy Clin Immunol. 2018 Feb;141(suppl
Precise definition of therapeutic response, cri- 2):AB101. doi:10.1016/j.jaci.2017.12.323
teria for optimal and suboptimal response,
criteria for continuation or discontinuation 6. Moore WC, Bleecker ER, Curran-Ever-
of b iologics, duration of biological treatment ett D, et al. Characterization of the se-
in patients who responded to therapy, rules vere asthma phenotype by the National
for switching to other biological drugs in pa- Heart, Lung, and Blood Institute’s Se-
tients who did not respond to therapy, rules vere Asthma Research Program. J Aller-
for combining biological drugs and the bio- gy Clin Immunol. 2007 Feb;119(2):405-
logical treatment of allergic comorbidities are 13.
just some of the questions that need to be an-
swered. 7. Jin HJ. Biological treatments for severe
asthma. Yeungnam Univ J Med. 2020
It is also necessary to clarify issues re- Oct;37(4):262-8.
lated to the identification of factors associat-
ed with treatment failure and the possibility 8. Porzsolt F, Rocha NG, Toledo-Arruda
of increasing the therapeutic response rate. A, et al. Efficacy and effectiveness trials
In particular, there is a great need to identify have different goals, use different tools,
new molecular targets in order to offer effec- and generate different messages. Prag-
tive treatments for those patients who do not mat Obs Res. 2015 Nov 4:6:47-54.
respond to currently available biologics11.
9. Menzies-Gow A, Szefler SJ, Busse WW.
Literature The Relationship of Asthma Biologics
to Remission for Asthma. J Allergy Clin
1. Global Initiative for Asthma. Global Immunol Pract. 2021 Mar;9(3):1090-8.
Strategy for Asthma Management and
Prevention [Internet]. [place unknown]: 10. Institute for Clinical and Economic Re-
Global Strategy for Asthma Manage- view. ICER Final Evidence Report
ment and Prevention; c2022 [cited 2018: Biologic Therapies for Treatment
September 10, 2021]. Available from: of Asthma Associated with Type 2 In-
http://www.ginasthma.org. flammation; Effectiveness, Value, and
Value-Based Price Benchmarks. Boston,
2. Bagnasco D, Passalacqua G, Camina- MA: Institute for Clinical and Econom-
ti M, et al. Evolving phenotypes to en- ic Review; 2018.
dotypes: is precision medicine achieva-
ble in asthma? Expert Rev Respir Med. 11. Agache I, Akdis CA, Akdis M, et al.
2020 Feb;14(2):163-72. EAACI Biologicals Guidelines-Recom-
mendations for severe asthma. Allergy.
3. Schoettler N, Strek ME. Recent Ad- 2021 Jan;76(1):14-44.
vances in Severe Asthma: From Pheno-
types to Personalized Medicine. Chest. 12. Busse W, Spector S, Rosén K, et al.
2020 Mar;157(3):516-28. High eosinophil count: a potential bio-
marker for assessing successful omali-
4. Porsbjerg C, Menzies-Gow A. Co-mor- zumab treatment effects. J Allergy Clin
bidities in severe asthma: Clinical im- Immunol. 2013 Aug;132(2):485-6.e.11.
pact and management. Respirology.
2017 May;22(4):651-61. 13. Bourgoin-Heck M, Amat F, Trouvé
C, et al. Omalizumab could be effec-
tive in children with severe eosinophil-
ic non-allergic asthma. Pediatr Allergy
Immunol. 2018 Feb;29(1):90-9.
sponses have not provided accurate answers et al. Characteristics of patients with se-
severe asthma forum 2: severe asthma - monitoring and treatable traits in severe asthma to a number of questions about long-term bi- vere asthma in our population. J Aller-
ological treatment in daily clinical practice. gy Clin Immunol. 2018 Feb;141(suppl
Precise definition of therapeutic response, cri- 2):AB101. doi:10.1016/j.jaci.2017.12.323
teria for optimal and suboptimal response,
criteria for continuation or discontinuation 6. Moore WC, Bleecker ER, Curran-Ever-
of b iologics, duration of biological treatment ett D, et al. Characterization of the se-
in patients who responded to therapy, rules vere asthma phenotype by the National
for switching to other biological drugs in pa- Heart, Lung, and Blood Institute’s Se-
tients who did not respond to therapy, rules vere Asthma Research Program. J Aller-
for combining biological drugs and the bio- gy Clin Immunol. 2007 Feb;119(2):405-
logical treatment of allergic comorbidities are 13.
just some of the questions that need to be an-
swered. 7. Jin HJ. Biological treatments for severe
asthma. Yeungnam Univ J Med. 2020
It is also necessary to clarify issues re- Oct;37(4):262-8.
lated to the identification of factors associat-
ed with treatment failure and the possibility 8. Porzsolt F, Rocha NG, Toledo-Arruda
of increasing the therapeutic response rate. A, et al. Efficacy and effectiveness trials
In particular, there is a great need to identify have different goals, use different tools,
new molecular targets in order to offer effec- and generate different messages. Prag-
tive treatments for those patients who do not mat Obs Res. 2015 Nov 4:6:47-54.
respond to currently available biologics11.
9. Menzies-Gow A, Szefler SJ, Busse WW.
Literature The Relationship of Asthma Biologics
to Remission for Asthma. J Allergy Clin
1. Global Initiative for Asthma. Global Immunol Pract. 2021 Mar;9(3):1090-8.
Strategy for Asthma Management and
Prevention [Internet]. [place unknown]: 10. Institute for Clinical and Economic Re-
Global Strategy for Asthma Manage- view. ICER Final Evidence Report
ment and Prevention; c2022 [cited 2018: Biologic Therapies for Treatment
September 10, 2021]. Available from: of Asthma Associated with Type 2 In-
http://www.ginasthma.org. flammation; Effectiveness, Value, and
Value-Based Price Benchmarks. Boston,
2. Bagnasco D, Passalacqua G, Camina- MA: Institute for Clinical and Econom-
ti M, et al. Evolving phenotypes to en- ic Review; 2018.
dotypes: is precision medicine achieva-
ble in asthma? Expert Rev Respir Med. 11. Agache I, Akdis CA, Akdis M, et al.
2020 Feb;14(2):163-72. EAACI Biologicals Guidelines-Recom-
mendations for severe asthma. Allergy.
3. Schoettler N, Strek ME. Recent Ad- 2021 Jan;76(1):14-44.
vances in Severe Asthma: From Pheno-
types to Personalized Medicine. Chest. 12. Busse W, Spector S, Rosén K, et al.
2020 Mar;157(3):516-28. High eosinophil count: a potential bio-
marker for assessing successful omali-
4. Porsbjerg C, Menzies-Gow A. Co-mor- zumab treatment effects. J Allergy Clin
bidities in severe asthma: Clinical im- Immunol. 2013 Aug;132(2):485-6.e.11.
pact and management. Respirology.
2017 May;22(4):651-61. 13. Bourgoin-Heck M, Amat F, Trouvé
C, et al. Omalizumab could be effec-
tive in children with severe eosinophil-
ic non-allergic asthma. Pediatr Allergy
Immunol. 2018 Feb;29(1):90-9.
